AVEO Pharmaceuticals (AVEO Pharmaceuticals) Change In Receivables : $-10.26 Mil (TTM As of Sep. 2022)

View and export this data going back to 2010. Start your Free Trial

What is AVEO Pharmaceuticals Change In Receivables?

AVEO Pharmaceuticals's change in receivables for the quarter that ended in Sep. 2022 was $-3.64 Mil. It means AVEO Pharmaceuticals's Accounts Receivable increased by $3.64 Mil from Jun. 2022 to Sep. 2022 .

AVEO Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2021 was $-10.40 Mil. It means AVEO Pharmaceuticals's Accounts Receivable increased by $10.40 Mil from Dec. 2020 to Dec. 2021 .

AVEO Pharmaceuticals's Accounts Receivable for the quarter that ended in Sep. 2022 was $18.72 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. AVEO Pharmaceuticals's Days Sales Outstanding for the three months ended in Sep. 2022 was 56.09.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. AVEO Pharmaceuticals's liquidation value for the three months ended in Sep. 2022 was $19.60 Mil.

AVEO Pharmaceuticals Change In Receivables Historical Data

The historical data trend for AVEO Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVEO Pharmaceuticals Change In Receivables Chart

AVEO Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Change In Receivables

Get a 7-Day Free Trial

0.63

-2.62

1.40

0.43

-10.40

AVEO Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Change In Receivables	Get a 7-Day Free Trial															-3.92	-2.09	-2.17	-2.36	-3.64

AVEO Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.26 Mil.

AVEO Pharmaceuticals (NAS:AVEO) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

AVEO Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Sep. 2022 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	18.717	/	30.449	*	91
=	56.09

2. In Ben Graham's calculation of liquidation value, AVEO Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

AVEO Pharmaceuticals's liquidation value for the quarter that ended in Sep. 2022 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	77.398	-	72.388	+	0.75 * 18.717	+	0.5 * 1.106
=	19.60

AVEO Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of AVEO Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

AVEO Pharmaceuticals (AVEO Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (NAS:AVEO) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Winter Street, Boston, MA, USA, 02108

Website

https://www.aveooncology.com

AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.

Executives

Jebediah Ledell	officer: Chief Operating Officer	C/O AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Michael P Bailey	director, officer: President & CEO	IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Michael Ferraresso	officer: Chief Commercial Officer	AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Kevin Joseph Cullen	director	AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Epperly Corinne	director	AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Forest Baskett	10 percent owner
Joshua Makower	10 percent owner	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Scott D Sandell	10 percent owner
Growth Equity Opportunities Iv, Llc	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Erick Lucera	officer: Chief Financial Officer	138 THISTLE ROAD, NORTH ANDOVER MA 08145
Scarlett Spring	director	AVEO PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Peter J Barris	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202